Why it matters
SALVOVAR is a European clinical project funded by the Horizon program, which aims to improve the treatment of patients with poor prognosis ovarian cancer after neoadjuvant chemotherapy. Specifically, the project is conducting a pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose and dosing schedule with the SALVage (SALVOVAR) weekly dose-dense regimen in patients with poor prognostic OVARian (SALVOVAR) cancers based on the poor tumor primary chemosensitivity and incomplete debulking surgery. It will provide diagnostic tools to help identify this group of patients and potentially provide a therapeutic solution for them, which will be easily implementable in routine at a low-price in any center. Led by Lyon University Hospital (HCL) and supported by ARCAGY-GINECO and ENGOT, it involves six countries (UK, France, Italy, Czech Republic, Israel and the Netherlands) and 100 recruitment centers. What ECPC does
What ECPC does
ECPCP leads the Dissemination, Communication and Exploitation of the project to provide information, tools and study results to key stakeholders in order to increase the impact of the project; improve outcomes for patients and their families; and improve quality, access and equity of care across Europe.
Funded by the EU.